Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

MRNA profiling by array for pancreatic ductal adenocarcinoma for clinical application

ABSTRACT: We performed combined gene expression analysis and targeted gene sequencing of 309 consecutive patients from a multicenter consortium.

ORGANISM(S): Homo sapiens

SUBMITTER: Elarouci Nabila

PROVIDER: E-MTAB-6134 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

Puleo Francesco F Nicolle Rémy R Blum Yuna Y Cros Jérôme J Marisa Laetitia L Demetter Pieter P Quertinmont Eric E Svrcek Magali M Elarouci Nabila N Iovanna Juan J Franchimont Denis D Verset Laurine L Galdon Maria Gomez MG Devière Jacques J de Reyniès Aurélien A Laurent-Puig Pierre P Van Laethem Jean-Luc JL Bachet Jean-Baptiste JB Maréchal Raphaël R

Gastroenterology 20180827 6

<h4>Background & aims</h4>Genomic studies have revealed subtypes of pancreatic ductal adenocarcinoma (PDA) based on their molecular features, but different studies have reported different classification systems. It is a challenge to obtain high-quality, freshly frozen tissue for clinical analysis and determination of PDA subtypes. We aimed to redefine subtypes of PDA using a large number of formalin-fixed and paraffin-embedded PDA samples, which are more amenable to routine clinical evaluation.< ...[more]

PMID: 30165049

Similar Datasets

Project description:Background: Only a subset of radically-resected pancreatic ductal adenocarcinoma (PDAC) patients benefit from chemotherapy, and identification of novel prognostic factors is warranted. Recently miRNAs emerged as diagnostic biomarkers and innovative therapeutic targets, while high-throughput arrays are opening new opportunities to evaluate whether they can also predict clinical outcome. The present study evaluated whether comprehensive miRNA expression profiling correlated with overall survival (OS) in resected PDAC patients. Methodology/Principal Findings: High-resolution miRNA profiles were obtained with the Toray’s 3D-GeneTM miRNA chip, detecting more than 1200 types of human miRNA. RNA was isolated from paraffin-embedded primary tumors of 26 radically resected stage-pT3N1 homogeneously treated patients (adjuvant gemcitabine 1000mg/m2/day, days-1/8/15, every 28days), carefully selected according to their outcome (OS<12 vs. OS>30 months, i.e. short/long-OS). Highly stringent statistics included t-test, distance matrix with Spearman-ranked correlation, and iterative approaches. Unsupervised hierarchical analysis revealed that PDAC specimens clustered according to their short/long-OS classification, while the feature selection algorithm RELIEF identified the top-4 discriminating miRNAs between the two groups. These miRNAs target more than 1500 transcripts, including 169 targeted by two or more of these miRNAs. MiR-211 emerged as the best discriminating miRNA, with significantly higher expression in long- vs. short-OS patients. The expression of this miRNA was subsequently assessed by quantitative-PCR in an independent cohort of laser microdissected tumors from 60 resected stage-pT3N1 PDAC patients treated with the same gemcitabine regimen. Patients with low miR-211 expression according to median value had a significantly shorter median OS (14.8, 95%CI=13.1-16.5, vs. 25.7 months, 95%CI=16.2-35.1, log-rank P=0.004). Multivariate analysis demonstrated that low miR-211 expression was an independent factor of poor prognosis (hazard ratio 2.3, P=0.03) after adjusting for all the factors influencing outcome. 19 samples, duplicated gene spots

Dataset Information

MRNA profiling by array for pancreatic ductal adenocarcinoma for clinical application

Publications

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure